179 results on '"Moideen, Kadar"'
Search Results
2. Plasma adipocytokines distinguish tuberculous lymphadenitis from pulmonary tuberculosis
3. Effect of anti-tuberculosis treatment on the systemic levels of tissue inhibitors of metalloproteinases in tuberculosis – Diabetes co-morbidity
4. Diminished systemic levels of antimicrobial peptides in tuberculous lymphadenitis and their reversal after anti-tuberculosis treatment
5. Diminished type 1 and type 17 cytokine expressing - Natural killer cell frequencies in tuberculous lymphadenitis
6. Immune Profiles in Multisystem Inflammatory Syndrome in Children with Cardiovascular Abnormalities
7. Systemic RAGE ligands are upregulated in tuberculosis individuals with diabetes co-morbidity and modulated by anti-tuberculosis treatment and metformin therapy
8. Plasma chemokines are biomarkers of disease severity, higher bacterial burden and delayed sputum culture conversion in pulmonary tuberculosis
9. Modulation of dendritic cell and monocyte subsets in tuberculosis-diabetes co-morbidity upon standard tuberculosis treatment
10. Low body mass index is associated with diminished plasma cytokines and chemokines in both active and latent tuberculosis
11. Impaired Cytokine but Enhanced Cytotoxic Marker Expression in Mycobacterium tuberculosis–Induced CD8 + T Cells in Individuals With Type 2 Diabetes and Latent Mycobacterium tuberculosis Infection
12. Elevated levels of matrix metalloproteinases reflect severity and extent of disease in tuberculosis-diabetes co-morbidity and are predominantly reversed following standard anti-tuberculosis or metformin treatment
13. Enhanced Severe Acute Respiratory Syndrome Coronavirus 2 Antigen–Specific Systemic Immune Responses in Multisystem Inflammatory Syndrome in Children and Reversal After Recovery
14. Differential Frequencies of Intermediate Monocyte Subsets Among Individuals Infected With Drug-Sensitive or Drug-Resistant Mycobacterium tuberculosis
15. Reduced systemic and mycobacterial antigen-stimulated concentrations of IL-1β and IL-18 in tuberculous lymphadenitis
16. Heightened Microbial Translocation Is a Prognostic Biomarker of Recurrent Tuberculosis
17. Enhanced SARS-CoV-2-Specific CD4+ T Cell Activation and Multifunctionality in Late Convalescent COVID-19 Individuals
18. High Dimensionality Reduction and Immune Phenotyping of Natural Killer and Invariant Natural Killer Cells in Latent Tuberculosis-Diabetes Comorbidity
19. Multi-Dimensionality Immunophenotyping Analyses of MAIT Cells Expressing Th1/Th17 Cytokines and Cytotoxic Markers in Latent Tuberculosis Diabetes Comorbidity
20. Acute Phase Proteins Are Baseline Predictors of Tuberculosis Treatment Failure
21. Decreased Frequencies of Gamma/Delta T Cells Expressing Th1/Th17 Cytokine, Cytotoxic, and Immune Markers in Latent Tuberculosis-Diabetes/Pre-Diabetes Comorbidity
22. Profiling leucocyte subsets in tuberculosis–diabetes co-morbidity
23. Helminth Coinfection Is Associated With Enhanced Plasma Levels of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Tuberculous Lymphadenitis
24. Reduced neutrophil granular proteins and post-treatment modulation in tuberculous lymphadenitis
25. Altered plasma levels of βC and γC chain cytokines and post-treatment modulation in tuberculous lymphadenitis
26. Association of Plasma Matrix Metalloproteinase and Tissue Inhibitors of Matrix Metalloproteinase Levels With Adverse Treatment Outcomes Among Patients With Pulmonary Tuberculosis
27. Enhanced SARS-CoV-2-Specific CD4 + T Cell Activation and Multifunctionality in Late Convalescent COVID-19 Individuals.
28. Diminished Frequencies of Cytotoxic Marker Expressing T- and NK Cells at the Site of Mycobacterium tuberculosis Infection
29. Plasma Chemokines Are Baseline Predictors of Unfavorable Treatment Outcomes in Pulmonary Tuberculosis
30. Altered systemic levels of acute phase proteins in tuberculous lymphadenitis and modulation after treatment
31. Strongyloides stercoralis Coinfection Is Associated With Greater Disease Severity, Higher Bacterial Burden, and Elevated Plasma Matrix Metalloproteinases in Pulmonary Tuberculosis
32. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Are Potential Biomarkers of Pulmonary and Extra-Pulmonary Tuberculosis
33. Heightened systemic levels of anti-inflammatory cytokines in pulmonary tuberculosis and alterations following anti-tuberculosis treatment
34. Heterogeneity in the cytokine profile of tuberculosis – diabetes co-morbidity
35. Plasma Chemokines Are Baseline Predictors of Unfavorable Treatment Outcomes in Pulmonary Tuberculosis.
36. Plasma Eicosanoid Levels in Tuberculosis and Tuberculosis-Diabetes Co-morbidity Are Associated With Lung Pathology and Bacterial Burden
37. Enhanced Mycobacterial Antigen–Induced Pro-Inflammatory Cytokine Production in Lymph Node Tuberculosis
38. Plasma Proinflammatory Cytokines Are Markers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis
39. Elevated circulating levels of monocyte activation markers among tuberculosis patients with diabetes co‐morbidity
40. Altered circulating levels of B cell growth factors and their modulation upon anti-tuberculosis treatment in pulmonary tuberculosis and tuberculous lymphadenitis
41. Diminished circulating plasma and elevated lymph node culture supernatant levels of IL-10 family cytokines in tuberculous lymphadenitis
42. Altered Systemic Adipokine Levels in Pulmonary Tuberculosis and Changes following Treatment
43. Modulation of Th1/Tc1 and Th17/Tc17 responses in pulmonary tuberculosis by IL-20 subfamily of cytokines
44. Monocyte Subsets: Phenotypes and Function in Tuberculosis Infection
45. Heightened Systemic Levels of Neutrophil and Eosinophil Granular Proteins in Pulmonary Tuberculosis and Reversal following Treatment
46. Heightened circulating levels of antimicrobial peptides in tuberculosis—Diabetes co-morbidity and reversal upon treatment
47. Prediabetes is associated with the modulation of antigen-specific Th1/Tc1 and Th17/Tc17 responses in latent Mycobacterium tuberculosis infection
48. Tuberculous Lymphadenitis Is Associated with Enhanced Baseline and Antigen-Specific Induction of Type 1 and Type 17 Cytokines and Reduced Interleukin-1β (IL-1β) and IL-18 at the Site of Infection
49. Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of circulating angiogenic factors
50. Elevated circulating levels of monocyte activation markers among tuberculosis patients with diabetes co‐morbidity.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.